Pharmaceutical manufacturers of Etodolac

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Chemi S.p.A. is a prominent Italian pharmaceutical company specializing in the research, development, and manufacturing of high-quality generic drugs and active pharmaceutical ingredients (APIs). With over 50 years of experience, Chemi S.p.A. is renowned for its expertise in complex chemistry and its commitment to innovation. The company operates in various therapeutic areas, including oncology, cardiovascular diseases, and central nervous system disorders, providing advanced healthcare solutions to patients globally.

Lonza stands as a prominent supplier in the Pharma&Biotech and Specialty Ingredient markets on a global scale. Our utilization of science and technology allows us to develop a diverse range of products that promote healthier lives for both humans and animals, while also improving overall well-being. The selection includes active pharmaceutical ingredients, stem-cell therapies, drinking water sanitizers, industrial preservatives, microbial control solutions, vitamin B compounds, organic personal care ingredients, and agricultural services and products.

Polpharma Group serves as a top-tier pharmaceutical manufacturer in Europe and a reliable partner for pharmaceutical firms globally. With a wide range of products (Rx, CHC, APIs), expert services, and competencies across the value chain, along with extensive knowledge of local CEE/CIS markets, it provides distinct growth opportunities for B2B partners. Collaborating with Polpharma Group offers access to a supportive environment, guidance from skilled professionals, and cutting-edge resources. The company actively seeks partners across various areas of operation, from product development and production to commercial cooperation. Additionally, Polpharma API, a Poland-based CDMO specializing in active pharmaceutical ingredients (APIs), stands as a significant European API supplier, catering to pharmaceutical companies worldwide. The company is in the process of a $45 million manufacturing expansion, incorporating HPAPI and cryogenic technologies, with investments in a pilot plant and R&D capabilities. Operations are set to expand from mid-2023, with full completion expected by 2026.

The Zydus group is based in Ahmedabad, India, and is placed 4th in the Indian pharmaceutical sector. Zydus' global operations have a substantial presence in the regulated markets of the US, Europe (specifically France and Spain), and in the prominent markets of Latin America and South Africa. It also has a significant presence in 25 other developing markets around the world.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics. With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Polepharma has been organizing and advancing the pharmaceutical industry in France, specializing in the biopharmaceutical sector for two decades. It has developed into the leading European hub for drug production, facilitating collaboration between excellence centers and industry stakeholders. Polepharma is committed to three collective principles, including the bold ambition to position France as the global leader in pharmaceutical development. On the other hand, Polpharma is a prominent CDMO and API producer based in Poland. With over 70 years of expertise, it stands as the largest API manufacturer in Poland, offering a comprehensive range of materials from clinical quantities to market supply. The company has fully integrated its operations, covering R&D to manufacturing, to provide cost-effective and timely solutions to its clients. Furthermore, Polpharma has made significant investments to enhance its API plant in Starogard Gdanski, incorporating HPAPI and cryogenic technologies, along with a pilot plant and R&D capabilities.

Lunan Pharma is a prominent pharmaceutical firm dedicated to enhancing human well-being through the production and promotion of top-quality pharmaceutical products. The company achieved total sales revenues of 1.8 billion dollars in 2020 and is ranked among the top 22 in China.

Nifty Labs Private Limited was established in March 2005. The corporation has specialized in the production of Active Pharmaceutical Ingredients (APIs) and advanced Intermediates for APIs.

COSMA S. P. A. (established in 1977) and AMSA S. P. A. (established in 1953) are a pair of chemical facilities widely recognized globally and particularly valued in the occidental world and in the nations that adhere to the Pharmaceutical Inspection Convention (PIC). They are part of the CFM Group, a privately-owned company engaged in the fields of chemistry and pharmaceuticals since 1949

A trusted Indian pharmaceutical company with strong people and technology capabilities, providing affordable, high-quality products that meet the healthcare needs of people across the globe.

Established in 1977 and initially reviewed by the FDA in 1984, COSMA SpA stands as the primary facility within the group, specializing in high-volume APIs with a reaction volume surpassing 130 m3. A modern, cutting-edge expansion of production capabilities was completed in 2011 and 2012.